Tofacitinib in Acute Severe Ulcerative Colitis (TACOS): A Randomized Controlled Trial

医学 托法替尼 溃疡性结肠炎 安慰剂 优势比 内科学 置信区间 随机化 随机对照试验 人口 英夫利昔单抗 外科 类风湿性关节炎 疾病 替代医学 环境卫生 病理
作者
Arshdeep Singh,Manjeet Kumar Goyal,Vandana Midha,Ramit Mahajan,Kirandeep Kaur,Yogesh Gupta,Dharmatma Singh,Namita Bansal,Ramandeep Kaur,Shivam Kalra,Omesh Goyal,Varun Mehta,Ajit Sood
出处
期刊:The American Journal of Gastroenterology [American College of Gastroenterology]
卷期号:119 (7): 1365-1372 被引量:44
标识
DOI:10.14309/ajg.0000000000002635
摘要

INTRODUCTION: Intravenous corticosteroids are the mainstay of treatment of patients hospitalized with acute severe ulcerative colitis (ASUC). However, 30%–40% of the patients are refractory to corticosteroids. We investigated whether addition of tofacitinib to corticosteroids improved the treatment responsiveness in patients with ASUC. METHODS: This single-center, double-blind, placebo-controlled trial randomized adult patients with ASUC (defined by the Truelove Witts severity criteria) to receive either tofacitinib (10 mg thrice daily) or a matching placebo for 7 days while continuing intravenous corticosteroids (hydrocortisone 100 mg every 6 hours). The primary end point was response to treatment (decline in the Lichtiger index by >3 points and an absolute score <10 for 2 consecutive days without the need for rescue therapy) by day 7. The key secondary outcome was the cumulative probability of requiring initiation of infliximab or undergoing colectomy within 90 days following randomization. All analyses were performed in the intention-to-treat population. RESULTS: A total of 104 patients were randomly assigned to a treatment group (53 to tofacitinib and 51 to placebo). At day 7, response to treatment was achieved in 44/53 (83.01%) patients receiving tofacitinib vs 30/51 (58.82%) patients receiving placebo (odds ratio 3.42, 95% confidence interval 1.37–8.48, P = 0.007). The need for rescue therapy by day 7 was lower in the tofacitinib arm (odds ratio 0.27, 95% confidence interval 0.09–0.78, P = 0.01). The cumulative probability of need for rescue therapy at day 90 was 0.13 in patients who received tofacitinib vs 0.38 in patients receiving placebo (log-rank P = 0.003). Most of the treatment-related adverse effects were mild. One patient, receiving tofacitinib, developed dural venous sinus thrombosis. DISCUSSION: In patients with ASUC, combination of tofacitinib and corticosteroids improved treatment responsiveness and decreased the need for rescue therapy.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
大个应助科研通管家采纳,获得10
1秒前
大模型应助科研通管家采纳,获得10
1秒前
李健应助科研通管家采纳,获得10
1秒前
JamesPei应助科研通管家采纳,获得10
1秒前
打打应助科研通管家采纳,获得10
1秒前
Owen应助科研通管家采纳,获得10
1秒前
隐形曼青应助科研通管家采纳,获得10
1秒前
千寒完成签到,获得积分10
1秒前
浮游应助科研通管家采纳,获得10
1秒前
小洛完成签到,获得积分10
1秒前
斯文败类应助科研通管家采纳,获得10
1秒前
1秒前
科研通AI6应助科研通管家采纳,获得10
2秒前
浮游应助科研通管家采纳,获得10
2秒前
Orange应助科研通管家采纳,获得10
2秒前
彭于晏应助科研通管家采纳,获得10
2秒前
MJX应助科研通管家采纳,获得10
2秒前
aki应助科研通管家采纳,获得20
2秒前
浮游应助科研通管家采纳,获得10
2秒前
2秒前
2秒前
cdercder应助vvv采纳,获得70
3秒前
3秒前
量子星尘发布了新的文献求助10
3秒前
3秒前
3秒前
慧慧完成签到,获得积分10
5秒前
bkagyin应助lunar采纳,获得10
5秒前
元谷雪发布了新的文献求助10
6秒前
Tiger发布了新的文献求助10
7秒前
魔幻的砖头完成签到,获得积分10
7秒前
酷酷的笔记本应助阿发采纳,获得10
8秒前
David发布了新的文献求助10
8秒前
8秒前
8秒前
FashionBoy应助阿玖采纳,获得10
8秒前
老实新筠完成签到,获得积分10
9秒前
9秒前
10秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Iron toxicity and hematopoietic cell transplantation: do we understand why iron affects transplant outcome? 2000
List of 1,091 Public Pension Profiles by Region 1021
Teacher Wellbeing: Noticing, Nurturing, Sustaining, and Flourishing in Schools 1000
Efficacy of sirolimus in Klippel-Trenaunay syndrome 500
EEG in Childhood Epilepsy: Initial Presentation & Long-Term Follow-Up 500
Latent Class and Latent Transition Analysis: With Applications in the Social, Behavioral, and Health Sciences 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5480459
求助须知:如何正确求助?哪些是违规求助? 4581574
关于积分的说明 14381235
捐赠科研通 4510152
什么是DOI,文献DOI怎么找? 2471660
邀请新用户注册赠送积分活动 1458083
关于科研通互助平台的介绍 1431812